Everything below concerns melanotan II. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
=== Neodymium === The rare earth element Neodymium is extracted by di(2-ethyl-hexyl)phosphoric acid into hexane by an ion exchange mechanism. Neodymium can also be separated from dysprosium through selective precipitation of dysprosium with Cyanex 272 when the HNO3 concentration was 0.001 mol/L.
== Formylation reactions in biology == In biochemistry, the addition of a formyl functional group is termed "formylation". A formyl functional group consists of a carbonyl bonded to hydrogen. When attached to an R group, a formyl group is called an aldehyde. Formylation has been identified in several critical biological processes. Methionine was first discovered to be formylated in E. coli by Marcker and Sanger in 1964 and was later identified to be involved in the initiation of protein synthesis in bacteria and organelles. The formation of N-formylmethionine is catalyzed by the enzyme methionyl-tRNAMet transformylase. Additionally, two formylation reactions occur in the de novo biosynthesis of purines. These reactions are catalyzed by the enzymes glycinamide ribonucleotide (GAR) transformylase and 5-aminoimidazole-4-carboxyamide ribotide (AICAR) transformylase. More recently, formylation has been discovered to be a histone modification, which may modulate gene expression.
is a constant, and neither does it deal with the uniqueness of the Navier–Stokes equations with respect to any turbulence properties.) It is also worth pointing out that the components of the velocity vector are exactly those from the Pythagorean quadruple parametrization. Other choices of density and pressure are possible with the same velocity field:
In this case a second brand is added at the top of their left rear leg, the croup. The second brand aids in identifying a particular horse among the hundreds or thousands under care. This mark uses Arabic numerals 4 inches (10 cm) high and displays the horse's tag number. If a horse has undergone special medical treatment the hip brand is preceded by a letter code. A hip brand preceded by "LB" for example indicates that a mare was treated with fertility control by BLM before being released back onto the range.
Newsom has also been condemned and criticized by humanitarian and queer rights organizations such as the Human Rights Campaign, National Center for LGBTQ Rights, and the Los Angeles LGBT Center. The American Civil Liberties Union issued a statement saying it was "saddened and angered" by Newsom's conduct, calling on him to "lean into his role as a leader on LGBTQ+ issues and reject the hateful, extremist rhetoric". In 2026, Newsom vetoed a bill that would have protected transgender healthcare and abortion providers from being extradited to other states. In his veto message, he said he supported protecting these services and their providers but expressed concern about the executive function of extradition.
Sources: en.wikipedia.org
The first trailers Compulsion released as well as the early access version, featuring a short narrative sequence introducing the playable character Arthur, created the impression that the game would be a first-person action-adventure game with a linear narrative. These early versions of We Happy Few were frequently compared to BioShock, a first-person shooter with a strong narrative produced by Irrational Games on a triple-A budget, and well outside the class of game that Compulsion was seeking to make. Compulsion maintained it was aiming to produce a roguelike survival game with some light narrative elements, which was meant to be played repeatedly, with a complete playthrough taking only three to four hours. Compulsion was aware that early access had worked well for games that lacked a strong narrative, and thus focused the initial development within early access on the survival elements, planning to hold back on the narrative development until late in the process as they did not want to reveal the full story until late in development. Compulsion also found it difficult to convince players that story elements were coming for the game's final release. Compulsion learned that players from early access were much more interested in the game's narrative over the game's survival or roguelike mechanics. At one point, the studio tried to remove the survival elements leaving only the action-adventure gameplay, but felt this affected the balance and flavor of the title, since Wellington Wells was meant to be a society on the verge of collapse due to dwindling resources.
3,4-Dihydroxyphenylacetic acid (DOPAC) is a metabolite of the neurotransmitter dopamine. Dopamine can be metabolized into one of three substances. One such substance is DOPAC. Another is 3-methoxytyramine (3-MT). Both of these substances are degraded to form homovanillic acid (HVA). Both degradations involve the enzymes monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT), albeit in reverse order: MAO catalyzes dopamine to DOPAC, and COMT catalyzes DOPAC to HVA; whereas COMT catalyzes dopamine to 3-MT and MAO catalyzes 3-MT to HVA. The third metabolic end-product of dopamine is norepinephrine (noradrenaline).
== Distribution and habitat == Considered to be a least-concern species according to the International Union for Conservation of Nature, the coastal taipan occurs in northern Australia and southern New Guinea. Its range extends from north-western Western Australia, the Northern Territory, across Cape York Peninsula, and south in eastern Queensland into northern New South Wales (as far south as Grafton). The coastal taipan, though, is not found in regions where the maximum winter temperature is below 20 °C (68 °F). The second subspecies (O. s. canni ) is found throughout the island of New Guinea, with higher concentrations of the snake being found in the nation of Papua New Guinea. The coastal taipan can be found in a variety of different habitats, in warm, wetter, temperate to tropical coastal regions, monsoon forests, wet and dry sclerophyll forests and woodlands, and natural and artificial grassy areas, including grazing paddocks and disused rubbish tips. It appears to have become more common since the 1935 introduction of the cane toad. Whether this is because of reduced competition, as other large venomous snakes have declined after being poisoned by toads, or due to increased food supply of rodents is unclear. It has adapted well to sugarcane fields, where it thrives on the rodent population in the fields. In Far North Queensland in the Cape York Peninsula, it is usually found in open woodland areas. Thickets of introduced Lantana are also favoured habitat. The coastal taipan shelters in abandoned animal burrows, hollow logs, and piles of vegetation and litter.
The second main legislative body is the Council of the European Union, which is composed of different ministers of the member states. The heads of government of member states also convene a "European Council" (a distinct body) that the TEU article 15 defines as providing the 'necessary impetus for its development and shall define the general political directions and priorities'. It meets each six months and its President (currently former Belgian Prime Minister Charles Michel) is meant to 'drive forward its work', but it does not itself exercise 'legislative functions'. The Council does this: in effect this is the governments of the member states, but there will be a different minister at each meeting, depending on the topic discussed (e.g. for environmental issues, the member states' environment ministers attend and vote; for foreign affairs, the foreign ministers, etc.). The minister must have the authority to represent and bind the member states in decisions. When voting takes place it is weighted inversely to member state size, so smaller member states are not dominated by larger member states. In total there are 352 votes, but for most acts there must be a qualified majority vote, if not consensus. TEU article 16(4) and TFEU article 238(3) define this to mean at least 55 per cent of the Council members (not votes) representing 65 per cent of the population of the EU: currently this means around 74 per cent, or 260 of the 352 votes. This is critical during the legislative process.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.